Objectives: To identify in vivo MRI markers that might correlate with cerebral microinfarcts (CMIs) on autopsy in patients with cerebral amyloid angiopathy (CAA).
Cerebral microinfarcts (CMIs) are defined as microscopic lesions of ischemic tissue damage on standard histopathologic sections (figure, A). The prevalence of microinfarcts at autopsy is reported to range from 16% to 48% in different populations and has been associated with cognitive impairment. 1 Several pathologic studies found CMIs to be more common in patients with cerebral amyloid angiopathy (CAA) compared to those without CAA. 2 Although to date it is not feasible to fully quantify CMI burden, it has been suggested that $1 CMIs seen in routinely sampled sections are indicative of hundreds to thousands CMIs throughout the entire brain. 3 It is hypothesized that these high numbers and the widespread distribution of CMIs can affect cortical networks as a substantial contributor to neurologic dysfunction and dementia. 1, 4 In the context of CAA, MRI markers of cerebral small vessel disease (SVD) such as lobar cerebral microbleeds, cortical superficial siderosis (cSS), centrum semiovale perivascular spaces (CS-PVSs), and white matter hyperintensities (WMHs) appear to predict clinical outcomes in the disease (figure, B-E). 5 The relationship of CMIs to these established MRI markers has not yet been defined. The purpose of this study is to explore in vivo clinical MRI markers and their correlation with CMI found on autopsy in patients with CAA.
METHODS Standard protocol approvals, registrations, and patient consents. This study was performed with approval of the institutional review board of the Massachusetts General Hospital (protocol No. 2015P001177).
Patients. Patients were retrospectively identified from a neuropathologic CAA cohort (1997-2012) by a systematic keyword search of pathology reports and prospective clinical databases based on both pathologic evidence of mild, moderate, or severe CAA (from routinely collected brain autopsy) and available antemortem brain MRI sequences as previously described. 6 Pathologic data. Morphologic assessment was performed with hematoxylin-eosin, Congo red, and b-amyloid (Ab) immunohistochemistry stains, according to standardized neuropathologic assessment. Severity of vascular Ab deposition was rated and graded according to the method described by Vonsattel et al 7 by experienced neuropathologists. We categorized cases as severe CAA if the characteristic vessel-invessel appearance caused by amyloid deposition was observed in the examined Ab-stained sections. Nine standard hematoxylineosin-stained sections (6 cortical regions: midfrontal, middlesuperior temporal, inferior parietal, cingulate, hippocampus, and entorhinal; and 3 deep brain regions: anterior basal ganglia, anterior thalamus, and midbrain) were reviewed for the presence and number of CMIs as previously described. 3 Lesions were identified by finding cavitation, puckering, or discrete regions of pallor with cell loss and gliosis (screened with 310, confirmed with 320 objectives) and manually counted by 2 readers (S.J.v.V, trained in CMI reading, and C.M.W, a board-certified neuropathologist) blinded to in vivo MRI and clinical data (interrater agreement: Cohen k 5 0.75). A consensus meeting was performed that included a third reader (A.L., trained in CMI reading) in cases of disagreement (n 5 5).
Neuroimaging data and analysis. Imaging for all patients consisted of MRI scans performed with 1.5T or 3T scanners and included an axial T2*-weighted sequence, a sagittal T1, and an axial fluid-attenuated inversion recovery sequence. The MRI closest to death was examined if multiple MRIs were available. All MRIs were reviewed by researchers blinded to clinical and pathologic data by trained observers, according to STRIVE (Standards for Reporting Vascular Changes on Neuroimaging). 8 In short, microbleed presence and number were evaluated according to current consensus criteria, and on the basis of previously described increased risk of cognitive impairment, patients were dichotomized into #4 vs .4 microbleeds. 4 The presence and number of ICHs (.10 mm in diameter on T2*-weighted MRI scans) were also noted. The severity of cSS, defined as curvilinear patterns of low signal on T2*-weighted sequences in the superficial layers of the cerebral cortex, was classified as focal (restricted to #3 sulci) or disseminated ($4 sulci) in the absence of contiguous connection with a lobar ICH. We assessed CS-PVSs on axial T2-weighted MRIs using a previously described, 9 validated, 5-point visual rating scale (0 5 no PVSs, 1 # 10 PVSs, 2 5 11-20 PVSs, 3 5 21-40 PVSs, and 4 $ 40 PVSs). Volume of WMH was quantified with the use of a semiautomated, multistep protocol on axial fluid-attenuated inversion recovery sequences.
Statistical analysis. Categorical variables were compared by use of x 2 tests. Normally distributed continuous variables were compared with the unpaired t test, and skewed distributed data were analyzed with the Mann-Whitney U test. Frequency distribution of CMI in cortical vs deep brain regions was compared by use of the Fisher exact test. Forced entry logistic regression analysis was used to determine whether microbleeds were independently associated with the presence of CMIs. Entered variables are presented with their odds ratio, standard error, 95% confidence interval, and p value after adjustment for confounding variables. A value of p , 0.05 was considered statistically significant. Statistical analyses were performed with SPSS 22.0. 
RESULTS
We identified 49 patients with CAA who met the inclusion criteria. the concept of mixed SVD: simultaneously occurring ischemic and hemorrhagic disease in a single SVDrelated disorder. The association of CMIs with microbleeds could be related to damage to vessel continuity caused by CAA pathology. While the characteristic accumulation of Ab within the arterial media and adventitia likely leads to vessel fragility and hemorrhage, amyloid deposits are also thought to lead to ischemia by thickening of the vessel wall and vessel occlusion in CAA. 3 Our results suggest that CMI burden in patients with CAA may in part be related to similar pathologic mechanisms underlying microbleeds, representing another consequence of vascular Ab accumulation. Indeed, a recent study has shown that the histopathologic substrate underlying MRIdefined microbleeds is heterogeneous and includes vasculopathies and hemorrhagic microinfarctions. 10 We did not observe an association with other MRI markers of CAA-related SVD. The reason may be that these other markers have distinct pathophysiologic mechanisms. Blood leaking from CAA-affected superficial cortical and leptomeningeal vessels is thought to give rise to the signal abnormalities characteristic of cSS on in vivo MRI, while CS-PVS enlargement could be related to drainage impairment of interstitial fluid and WMH to chronic ischemic changes in deeper regions of the brain. 2, 11 Similar to microinfarcts, WMHs are considered to be of ischemic nature; however, we did not find an association between these 2 lesions. This is consistent with a previous pathologic study in which increased WMH burden was not associated with the presence of CMI on pathology, although there appeared to be a trend toward greater CAA severity. 12 The data may suggest that these lesions have different underlying mechanisms.
We found CMIs in more than one-third of the CAA cases included in this study. This high prevalence of CMI pathology is in line with previous studies and may indicate an overall burden of several hundreds to thousands in the entire brain. 1, 3 Because the majority of CMIs remain undetected by conventional MRI, a surrogate marker to indirectly quantify or monitor growing CMI burden could be of great value. 1, 2, 8 Limitations of this study lie in its retrospective nature and possible selection bias in this hospital-based cohort. The relatively small number of patients, the interval between neuroimaging and pathologic evaluation, and the cross-sectional design limit generalizability regarding the prognostic significance of microbleeds for the presence of CMIs. The strength of this work is the combination of detailed pathologic examinations and in vivo imaging data in a defined patient population.
In conclusion, CMIs are common in patients with CAA, and there is a strong association between CMI at autopsy and microbleeds on MRI obtained during life. This suggests a shared underlying pathophysiologic mechanism. Further studies are needed to evaluate whether microbleeds observed on MRI represent a robust surrogate for CMI burden and to explore the association between microbleeds and cognitive impairment. 
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